Stevens First Principles Investment Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-200	Closed	-$22K	–	187
2015 Q2	$22K	Buy	+200	New	+$21.5K	0.01%	170
2014 Q4	–	Sell	-100	Closed	-$6K	–	213
2014 Q3	$6K	Sell	100 -150	-60%	-$6.46K	﹤0.01%	210
2014 Q2	$11K	Buy	+250	New	+$10.2K	0.01%	184

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's AGIO Position: Q3 2015 in Review

Stevens First Principles Investment Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2015, closing a stake of 200 shares — an estimated $22K sold.

Stevens First Principles Investment Advisors first reported a position in AGIO in Q2 2014 and held it in 3 quarters. The position peaked at $22K in Q2 2015. 151 funds tracked by Wall St. Rank hold AGIO as of Q3 2015.

Stevens First Principles Investment Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 200 Agios Pharmaceuticals shares in Q3 2015, an estimated $22K.
Stevens First Principles Investment Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Stevens First Principles Investment Advisors's Agios Pharmaceuticals position peaked at $22K in Q2 2015.
151 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.